Combined Neprilysin and Renin–Angiotensin System Inhibition in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis
Open Access
- 30 June 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 18 (10) , 1238-1243
Abstract
Aims The combined neprilysin/renin–angiotensin system (RAS) inhibitor sacubitril/valsartan reduced cardiovascular death or heart failure hospitalization, cardiovascular death, and all‐cause mortality in a large outcomes trial. While sacubitril/valsartan is the only currently available drug in its class, there are two prior clinical trials in heart failure with omapatrilat, another combined neprilysin/RAS inhibitor. Using all available evidence can inform clinicians and policy‐makers. Methods and results We performed a meta‐analysis using data from three trials in heart failure with reduced EF that compared combined neprilysin/RAS inhibition with RAS inhibition alone and reported clinical outcomes: IMPRESS (n = 573), OVERTURE (n = 5770), and PARADIGM‐HF (n = 8399). We assessed the pooled hazard ratio (HR) for all‐cause death or heart failure hospitalization, and for all‐cause mortality in random‐effects models, comparing combined neprilysin/RAS inhibition with ACE inhibition alone. The composite outcome of death or heart failure hospitalization was reduced numerically in patients receiving combined neprilysin/RAS inhibition in all three trials, with a pooled HR of 0.86, 95% confidence interval (CI) 0.76–0.97, P = 0.013. For the endpoint of all‐cause mortality, the pooled HR was 0.88, 95% CI 0.80–0.98, P = 0.021. Combined neprilysin/RAS inhibition compared with ACE inhibition was associated with more hypotension, but less renal dysfunction and hyperkalaemia in all three trials. Conclusions Pooled estimates from three trials with two separate drugs of combined neprilysin/RAS inhibition support the use of combined neprilysin/RAS inhibition in heart failure with reduced EF.Keywords
Funding Information
- Novartis
- Bristol-Myers Squibb
This publication has 22 references indexed in Scilit:
- Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)European Journal of Heart Failure, 2013
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyThe Lancet, 2010
- Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin‐mediated angioedemaBritish Journal of Pharmacology, 2008
- Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failureKidney International, 2005
- Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart FailureCirculation, 2002
- Renal response to candoxatrilat in patients with heart failureJACC, 1995
- A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction.Journal of Clinical Investigation, 1995
- Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.Circulation Research, 1992
- Candoxatril, a neutral endopeptidase inhibitorJournal Of Hypertension, 1992
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986